Derived from okadaic acid by reduction of the carboxyl group. Inactive against protein phosphatases.
Product Details
| Formula: | C44H70O12 |
| |
| MW: | 791.1 |
| |
| Source: | Semisynthetic derivative of okadaic acid. Okadaic acid isolated from Prorocentrum lima. |
| |
| CAS: | 131959-12-1 |
| |
| Purity: | ≥90% |
| |
| Appearance: | Colorless solid. |
| |
| Solubility: | Soluble in methanol or DMSO. |
| |
| Shipping: | Blue Ice |
| |
| Long Term Storage: | -20°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
The total activity of a mixture of okadaic acid-group compounds can be calculated by those of individual analogues in a phosphoprotein phosphatase 2a assay: C. Albano, et al.; Toxicon
53, 631 (2009),
Abstract;
Regulation of immunoglobulin E-mediated secretion by protein phosphatases in human basophils and mast cells of skin and lung: R. Bastan, et al.; Eur. J. Pharmacol.
430, 135 (2001),
Abstract;
An okadaic acid-sensitive pathway involved in the phenobarbital-mediated induction of CYP2B gene expression in primary rat hepatocyte cultures: J.S. Sidhu & C.J. Omiecinski; J. Pharmacol. Exp. Ther.
282, 1122 (1997),
Abstract;
Preliminary characterization of the role of protein serine/threonine phosphatases in the regulation of human lung mast cell function: M.J. Peirce, et al.; Br. J. Pharmacol.
120, 239 (1997),
Abstract;
Regulation of human basophil function by phosphatase inhibitors: M.J. Peirce, et al.; Br. J. Pharmacol.
119, 446 (1996),
Abstract;
Characterization of natural toxins with inhibitory activity against serine/threonine protein phosphatases: R.E. Honkanen, et al.; Toxicon
32, 339 (1994),
Abstract;
Regulation of human lung mast cell function by phosphatase inhibitors: P.T. Peachell & M.R. Munday; J. Immunol.
151, 3808 (1993),
Abstract;
